首页> 外文期刊>Analytical chemistry >Direct Quantification of Circulating MiRNAs in Different Stages of Nasopharyngeal Cancerous Serum Samples in Single Molecule Level with Total Internal Reflection Fluorescence Microscopy
【24h】

Direct Quantification of Circulating MiRNAs in Different Stages of Nasopharyngeal Cancerous Serum Samples in Single Molecule Level with Total Internal Reflection Fluorescence Microscopy

机译:用全内反射荧光显微镜直接定量检测单个分子水平上鼻咽癌血清样品不同阶段的循环miRNA。

获取原文
获取原文并翻译 | 示例
       

摘要

MicroRNAs (miRNAs) are small noncoding RNAs that regulate human gene expression at the post-transcriptional level. Growing evidence indicates that the expression profile of miRNAs is highly correlated with the occurrence of human diseases including cancers. Playing important roles in complex gene regulation processes, the aberrant expression pattern of various miRNAs is implicated in different types and even stages of cancer. Besides localizing in cells, many of these miRNAs are found circulating around the body in a wide variety of fluids such as urine, serum and saliva. Surprisingly, these extracellular circulating miRNAs are highly stable and resistant to degradation, and therefore, are considered as promising biomarkers for early cancer diagnostic via noninvasive extraction from body fluids. Unfortunately, the abundance of these small RNAs is ultralow in the body fluids, making it challenging to quantify them in complex sample matrixes. Establishing a sensitive, specific yet simple assay for an accurate quantification of circulating miRNAs is therefore desirable. Our group previously reported a sensitive and specific detection assay of miRNAs in single molecule level with the aid of total internal reflection fluorescence microscopy. In this work, we advanced the assay to differentiate the expression of a nasopharyngeal carcinoma (NPC) up-regulator hsa-mir-205 (mir-205) in serum collected from patients of different stages of NPC. To overcome the background matrix interference in serum, a locked nucleic acid-modified molecular beacon (LNA/MB) was applied as the detection probe to hybridize, capture and detect target mir-205 in serum matrix with enhanced sensitivity and specificity. A detection limit of 500 fM was achieved. The as-developed method was capable of differentiating NPC stages by the level of mir-205 quantified in serum with only 10 μL of serum and the whole assay can be completed in 1 h. The experimental results agreed well with those previously reported whereas the quantity of miR-205 determined by our assay was found comparable to that of quantitative reverse transcription polymerase chain reaction (qRT-PCR), supporting that this assay can be served as a promising noninvasive detection tool for early NPC diagnosis, monitoring and staging.
机译:微小RNA(miRNA)是小的非编码RNA,可在转录后水平调节人类基因的表达。越来越多的证据表明,miRNA的表达谱与人类疾病(包括癌症)的发生高度相关。在复杂的基因调控过程中发挥重要作用,各种miRNA的异常表达模式与癌症的不同类型甚至阶段有关。除了定位于细胞外,还发现许多这些miRNA在人体中以各种液体(如尿液,血清和唾液)循环。令人惊讶地,这些细胞外循环miRNA高度稳定并且对降解具有抗性,因此被认为是通过从体液中进行非侵入性提取来进行早期癌症诊断的有前途的生物标记。不幸的是,这些小RNA的丰度在体液中极低,这使其难以在复杂的样品基质中进行定量。因此,需要建立一种灵敏的,特异性的但简单的测定法来精确定量循环miRNA。我们的小组先前报道了借助全内反射荧光显微镜技术对单分子水平的miRNA进行灵敏和特异性的检测。在这项工作中,我们进行了该测定,以区分从不同阶段的NPC患者收集的血清中的鼻咽癌(NPC)上调剂hsa-mir-205(mir-205)的表达。为了克服血清对背景基质的干扰,将锁定的核酸修饰分子信标(LNA / MB)作为检测探针,以增强的灵敏度和特异性杂交,捕获和检测血清mir-205中的靶标。检测限达到500 fM。所开发的方法能够通过仅含10μL血清的血清中mir-205的定量水平来区分NPC阶段,整个检测过程可在1小时内完成。实验结果与先前报道的结果相吻合,而我们的测定法确定的miR-205的量可与定量逆转录聚合酶链反应(qRT-PCR)的量相提并论,支持该测定法可作为有前途的无创检测方法NPC早期诊断,监测和分期的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号